TECTONIC THERAPEUTIC INC (TECX) competitors & alternatives
Health Care · NASDAQ
TECTONIC THERAPEUTIC INC (TECX)'s top competitors and alternatives — its most similar public companies — include United Therapeutics (UTHR), LIQUIDIA CORP (LQDA), TREVI THERAPEUTICS INC (TRVI), CRINETICS PHARMACEUTICALS INC (CRNX), Tenaya Therapeutics, Inc. (TNYA), RHYTHM PHARMACEUTICALS INC (RYTM), Insmed (INSM), Ionis Pharmaceuticals (IONS), MANNKIND CORP (MNKD), ATRIUM THERAPEUTICS INC (RNA), Roivant Sciences (ROIV) and ASTRAZENECA PLC (AZN). These are TECTONIC THERAPEUTIC INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TECX competitors & alternatives
-
United TherapeuticsUTHRHealth Care
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing…
$527.07 (as of 2026-07-22) · market cap $22.7B
-
LIQUIDIA CORPLQDAHealth Care
Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering,…
$87.04 (as of 2026-07-22) · market cap $7.7B
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
-
CRINETICS PHARMACEUTICALS INCCRNXHealth Care
A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across…
$83.72 (as of 2026-07-22) · market cap $8.9B
-
Tenaya Therapeutics, Inc.TNYAHealth Care
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine…
$0.79 (as of 2026-07-22) · market cap $171M
-
RHYTHM PHARMACEUTICALS INCRYTMHealth Care
Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related…
$103.97 (as of 2026-07-22) · market cap $7.1B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
MANNKIND CORPMNKDHealth Care
MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic…
$3.84 (as of 2026-07-22) · market cap $1.2B
-
ATRIUM THERAPEUTICS INCRNAHealth Care
Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in…
$12.17 (as of 2026-07-22) · market cap $210M
-
Roivant SciencesROIVHealth Care
Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of…
$34.91 (as of 2026-07-22) · market cap $25.1B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
Not quite? Describe exactly what you want →
Peers are TECTONIC THERAPEUTIC INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: TECTONIC THERAPEUTIC INC (TECX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.